Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Alemtuzumab in Treating Patients With Waldenstrom`s Macroglobulinemia

Study:

Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom`s Macroglobulinemia)

Rationale:

Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

Purpose:

This phase II trial is studying how well alemtuzumab works in treating patients with Waldenstrom`s macroglobulinemia.

Study Status: Withdrawn

Recruiting:
n/a

Condition Intervention Phase
Lymphoma Biological: alemtuzumab Phase 2

Verified by Jonsson Comprehensive Cancer Center January, 2013

Sponsored by: Jonsson Comprehensive Cancer Center
Information provided by: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00081068

Study Type: Interventional

Study Design: Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Jennifer Gansert, MD, PhD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site